Hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic Lupus Erithematosus and antiphospholipid syndrome

Objectives: to detect the prevalence of hyperhcy in SLE patients with and without antiphospholipid syndrom; to compare the Hcy leveis between those patients and healthy controis and to determine the correlation between hyperhcy and antiphospholipid antibodies. Patients and methods: we studied 44 SLE...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Onetti, Laura, Villafañe, Susana, Menso, Emilia, Denkard, Cristina, Gamron, Susana, Barberis, Gloria, Onetti, Carlos
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2005
Materias:
.
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/32470
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
id I10-R327-article-32470
record_format ojs
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-327
container_title_str Revista de la Facultad de Ciencias Médicas de Córdoba
language Español
format Artículo revista
topic .
.
spellingShingle .
.
Onetti, Laura
Villafañe, Susana
Menso, Emilia
Denkard, Cristina
Gamron, Susana
Barberis, Gloria
Onetti, Carlos
Hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic Lupus Erithematosus and antiphospholipid syndrome
topic_facet .
.
author Onetti, Laura
Villafañe, Susana
Menso, Emilia
Denkard, Cristina
Gamron, Susana
Barberis, Gloria
Onetti, Carlos
author_facet Onetti, Laura
Villafañe, Susana
Menso, Emilia
Denkard, Cristina
Gamron, Susana
Barberis, Gloria
Onetti, Carlos
author_sort Onetti, Laura
title Hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic Lupus Erithematosus and antiphospholipid syndrome
title_short Hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic Lupus Erithematosus and antiphospholipid syndrome
title_full Hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic Lupus Erithematosus and antiphospholipid syndrome
title_fullStr Hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic Lupus Erithematosus and antiphospholipid syndrome
title_full_unstemmed Hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic Lupus Erithematosus and antiphospholipid syndrome
title_sort hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic lupus erithematosus and antiphospholipid syndrome
description Objectives: to detect the prevalence of hyperhcy in SLE patients with and without antiphospholipid syndrom; to compare the Hcy leveis between those patients and healthy controis and to determine the correlation between hyperhcy and antiphospholipid antibodies. Patients and methods: we studied 44 SLE patients: 17 had antiphospholipid syndroni and 27 didn't have it, and we compared them to 24 healthy controis. Ah of them where checked clinically and with laboratory tests like anticardiolypin antibodies, lupus anticoagulant and Hcy. Hcy > 9 was considered abnormal. Patient who had hyperhcy were treated with folie acid+vitD6+vitB12 a month along. Statistical analysis: cualytative variables: chi square or Flscher's; cuantitative variables: Student's T test or Mann-Whitney's test. Results and conclutions: there were 35 trombotic inanifestations in 44 patients. Hyperhcy was present in 27 SLE patients (61,4%), 12 of them had antiphospholipid syndrom. Hcy concentrations patients Vs. controls was statisticaly different (p=0,002). There was also stastisticaly different the hcy concentration from SLE patients with SAF VS controls (p=0,003) and without SAF VS controis (p= 0,015). From 33 SLE patients, 20(33%) were aCL(+). 15(75%) of them had hiperhcy.
publisher Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
publishDate 2005
url https://revistas.unc.edu.ar/index.php/med/article/view/32470
work_keys_str_mv AT onettilaura hyperhomocystinemiaasathromboticriskfactorinpatientssufferlngfromsystemiclupuserithematosusandantiphospholipidsyndrome
AT villafanesusana hyperhomocystinemiaasathromboticriskfactorinpatientssufferlngfromsystemiclupuserithematosusandantiphospholipidsyndrome
AT mensoemilia hyperhomocystinemiaasathromboticriskfactorinpatientssufferlngfromsystemiclupuserithematosusandantiphospholipidsyndrome
AT denkardcristina hyperhomocystinemiaasathromboticriskfactorinpatientssufferlngfromsystemiclupuserithematosusandantiphospholipidsyndrome
AT gamronsusana hyperhomocystinemiaasathromboticriskfactorinpatientssufferlngfromsystemiclupuserithematosusandantiphospholipidsyndrome
AT barberisgloria hyperhomocystinemiaasathromboticriskfactorinpatientssufferlngfromsystemiclupuserithematosusandantiphospholipidsyndrome
AT onetticarlos hyperhomocystinemiaasathromboticriskfactorinpatientssufferlngfromsystemiclupuserithematosusandantiphospholipidsyndrome
AT onettilaura hiperhomocisteinemiacomofactorderiesgotromboticoenpacientesconlupuseritematososistemicoysindromeantifosfosfolipidico
AT villafanesusana hiperhomocisteinemiacomofactorderiesgotromboticoenpacientesconlupuseritematososistemicoysindromeantifosfosfolipidico
AT mensoemilia hiperhomocisteinemiacomofactorderiesgotromboticoenpacientesconlupuseritematososistemicoysindromeantifosfosfolipidico
AT denkardcristina hiperhomocisteinemiacomofactorderiesgotromboticoenpacientesconlupuseritematososistemicoysindromeantifosfosfolipidico
AT gamronsusana hiperhomocisteinemiacomofactorderiesgotromboticoenpacientesconlupuseritematososistemicoysindromeantifosfosfolipidico
AT barberisgloria hiperhomocisteinemiacomofactorderiesgotromboticoenpacientesconlupuseritematososistemicoysindromeantifosfosfolipidico
AT onetticarlos hiperhomocisteinemiacomofactorderiesgotromboticoenpacientesconlupuseritematososistemicoysindromeantifosfosfolipidico
first_indexed 2024-09-03T21:02:18Z
last_indexed 2024-09-03T21:02:18Z
_version_ 1809210239138922496
spelling I10-R327-article-324702021-06-29T17:30:11Z Hyperhomocystinemia as a thrombotic risk factor in patients sufferlng from systemic Lupus Erithematosus and antiphospholipid syndrome Hiperhomocisteinemia como factor de riesgo trombótico en pacientes con Lupus Eritematoso Sistémico y Síndrome antifosfosfolipídico . Onetti, Laura Villafañe, Susana Menso, Emilia Denkard, Cristina Gamron, Susana Barberis, Gloria Onetti, Carlos . . Objectives: to detect the prevalence of hyperhcy in SLE patients with and without antiphospholipid syndrom; to compare the Hcy leveis between those patients and healthy controis and to determine the correlation between hyperhcy and antiphospholipid antibodies. Patients and methods: we studied 44 SLE patients: 17 had antiphospholipid syndroni and 27 didn't have it, and we compared them to 24 healthy controis. Ah of them where checked clinically and with laboratory tests like anticardiolypin antibodies, lupus anticoagulant and Hcy. Hcy > 9 was considered abnormal. Patient who had hyperhcy were treated with folie acid+vitD6+vitB12 a month along. Statistical analysis: cualytative variables: chi square or Flscher's; cuantitative variables: Student's T test or Mann-Whitney's test. Results and conclutions: there were 35 trombotic inanifestations in 44 patients. Hyperhcy was present in 27 SLE patients (61,4%), 12 of them had antiphospholipid syndrom. Hcy concentrations patients Vs. controls was statisticaly different (p=0,002). There was also stastisticaly different the hcy concentration from SLE patients with SAF VS controls (p=0,003) and without SAF VS controis (p= 0,015). From 33 SLE patients, 20(33%) were aCL(+). 15(75%) of them had hiperhcy. Objetivos: Determinar la prevalencia de hiperhomocisteinemia (hiperhcy) en pacientes con lupus eritematoso sistémico (LES) con y sin síndrome antifosfolípido (SAF); comparar los niveles de homocisteína (Hcy) entre pacientes con LES (con y sin SAF asociado) y un grupo de controles Sanos y determinar la correlación entre hiperhcy y la presencia de anticuerpos antifosfolípidos. Pacientes y métodos: Se estudiaron 44 ptes con LES, portadores o no de SAF Se los dividió en 2 grupos: 17 con LES y SAF y 27 con LES sin SAF y se compararon con 24 controles sanos. A todos se les realizó interrogatorio, examen físico y pruebas de laboratorio: anticuerpos anticardiolipinas (aCL), anticoagulante lúpico y Hcy. Se consideró hiperhey a valores superiores a 9. A los ptcS con hiperhcy se los trató con ácido fólico + B6 + Hl 2 durante un mes. Análisis estadístico: variables cualitativas: Chi cuadrado o Exacta de F'iseher y cuantitativas: test T de Studcnt o Mann-Whitney test. Resultados y conclusiones: Hubo 35 manifestaciones trombóticas en los 44 pacientes. Se encontró Iliperhcy en 27 ptes con LES (614%), de los cuales 12 tenían SAE La diferencia entre los valores de Hcy de los pacientes con o sin SAE no fue significativa (p=0.42). Comparando las concentraciones de 1-ley entre pacientes y controles. la diferencia fue muy signilicaliva (p=0.002).Tanibién tuvo significación estadística la clifeiencia entre las concentraciones de 1-ley de los pacientes con LES sin SAE vs. controles (p=0,015) y LES con SAE Vs. controles (p=0003). A 33 pIes se les closó aCL: 20 (60,6%) luciuti (-e). De estos, 15 (75%) tenían hiperhcy. De los 27 pacientes con LES que tenían hiperhcy, sólo 18 cumplieron con el mes de tratamiento con a.fólico-tB6+B12. 16 de 18 (88.8%) flor irializaron o disminuyeron la 1-ley. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2005-09-25 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/32470 10.31053/1853.0605.v62.n3.32470 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 62 No. 3 (2005); 19 - 24 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 62 Núm. 3 (2005); 19 - 24 Revista da Faculdade de Ciências Médicas de Córdoba; v. 62 n. 3 (2005); 19 - 24 1853-0605 0014-6722 spa https://revistas.unc.edu.ar/index.php/med/article/view/32470/33234 Derechos de autor 2021 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0

Ejemplares similares